173 related articles for article (PubMed ID: 27367921)
1. Fluocinolone Acetonide Intravitreal Implant in the Visual Axis.
Moisseiev E; Morse LS
JAMA Ophthalmol; 2016 Sep; 134(9):1067-8. PubMed ID: 27367921
[No Abstract] [Full Text] [Related]
2. Fluocinolone acetonide for the treatment of diabetic macular edema.
Veritti D; Sarao V; Diplotti L; Samassa F; Lanzetta P
Expert Opin Pharmacother; 2017 Oct; 18(14):1507-1516. PubMed ID: 28764565
[TBL] [Abstract][Full Text] [Related]
3. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.
Campochiaro PA; Brown DM; Pearson A; Ciulla T; Boyer D; Holz FG; Tolentino M; Gupta A; Duarte L; Madreperla S; Gonder J; Kapik B; Billman K; Kane FE;
Ophthalmology; 2011 Apr; 118(4):626-635.e2. PubMed ID: 21459216
[TBL] [Abstract][Full Text] [Related]
4. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant.
Ciulla TA; Harris A; McIntyre N; Jonescu-Cuypers C
Expert Opin Pharmacother; 2014 May; 15(7):953-9. PubMed ID: 24661081
[TBL] [Abstract][Full Text] [Related]
5. [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].
Soubrane G; Behar-Cohen F
J Fr Ophtalmol; 2015 Feb; 38(2):159-67. PubMed ID: 25601517
[TBL] [Abstract][Full Text] [Related]
6. Introduction.
Puliafito CA
Ophthalmic Surg Lasers Imaging Retina; 2016 Apr; 47(4 Suppl):S4. PubMed ID: 27096288
[No Abstract] [Full Text] [Related]
7. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial.
Pearson PA; Comstock TL; Ip M; Callanan D; Morse LS; Ashton P; Levy B; Mann ES; Eliott D
Ophthalmology; 2011 Aug; 118(8):1580-7. PubMed ID: 21813090
[TBL] [Abstract][Full Text] [Related]
8. Fluocinolone acetonide intravitreal implant (Iluvien®): in diabetic macular oedema.
Sanford M
Drugs; 2013 Feb; 73(2):187-93. PubMed ID: 23335133
[TBL] [Abstract][Full Text] [Related]
9. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
[TBL] [Abstract][Full Text] [Related]
10. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.
Fusi-Rubiano W; Mukherjee C; Lane M; Tsaloumas MD; Glover N; Kidess A; Denniston AK; Palmer HE; Manna A; Morjaria R
BMC Ophthalmol; 2018 Feb; 18(1):62. PubMed ID: 29486754
[TBL] [Abstract][Full Text] [Related]
11. Fluocinolone acetonide implantable device for diabetic retinopathy.
Schwartz SG; Flynn HW
Curr Pharm Biotechnol; 2011 Mar; 12(3):347-51. PubMed ID: 20939799
[TBL] [Abstract][Full Text] [Related]
12. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants.
Yang Y; Bailey C; Holz FG; Eter N; Weber M; Baker C; Kiss S; Menchini U; Ruiz Moreno JM; Dugel P; Lotery A;
Eye (Lond); 2015 Sep; 29(9):1173-80. PubMed ID: 26113503
[TBL] [Abstract][Full Text] [Related]
14. Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema.
Messenger WB; Beardsley RM; Flaxel CJ
Drug Des Devel Ther; 2013; 7():425-34. PubMed ID: 23737661
[TBL] [Abstract][Full Text] [Related]
15. Fluocinolone acetonide for the treatment of diabetic macular edema.
Haritoglou C; Mayer W; Wolf A
Expert Rev Clin Pharmacol; 2016; 9(3):367-74. PubMed ID: 26681198
[TBL] [Abstract][Full Text] [Related]
16. Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN
Syed YY
Drugs; 2017 Apr; 77(5):575-583. PubMed ID: 28283896
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies.
Pochopien M; Beiderbeck A; McEwan P; Zur R; Toumi M; Aballéa S
BMC Health Serv Res; 2019 Jan; 19(1):22. PubMed ID: 30626376
[TBL] [Abstract][Full Text] [Related]
18. Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting.
Elaraoud I; Andreatta W; Kidess A; Bhatnagar A; Tsaloumas M; Quhill F; Yang Y
BMC Ophthalmol; 2016 Jan; 16():3. PubMed ID: 26728265
[TBL] [Abstract][Full Text] [Related]
19. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema.
Currie CJ; Holden SE; Owens DR
Curr Med Res Opin; 2017 Oct; 33(sup2):33-43. PubMed ID: 28881150
[TBL] [Abstract][Full Text] [Related]
20. [Binocular Fluocinolone Acetonide Intravitreal Implant for Therapy-Resistant Diabetic Maculopathy].
Linz K; Auffarth GU; Kretz FT
Klin Monbl Augenheilkd; 2015 Oct; 232(10):1208-12. PubMed ID: 25853942
[No Abstract] [Full Text] [Related]
[Next] [New Search]
